# Elevation Oncology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/elevation-oncology

- Industry: Biotechnology
- Headquarters: New York, US
- Website: www.elevationoncology.com
- Total disclosed funding: $98M
- Latest round: Series B (Nov 10, 2020)
- Investors on record: 11

## About

Elevation Oncology, Inc. is a biopharmaceutical company dedicated to advancing precision medicine through innovative therapies for patients with genomically defined cancers.Founded in 2019 and headquartered in New York, US, Elevation Oncology, Inc. focuses on developing targeted therapies for cancer. Under the leadership of Shawn Leland, the company has completed a total of 3 deals, with the most recent funding round being an IPO on June 24, 2021, which raised USD 100.00 mn, bringing the total amount raised to USD 100.00 mn.Elevation Oncology specializes in precision oncology, delivering groundbreaking therapeutics aimed at treating specific cancer profiles based on genetic mutations. Their portfolio includes a range of targeted therapies that cater to patients with various types of cancer, ensuring tailored treatment options. The company targets a diverse clientele, including healthcare providers and oncology specialists, and markets its products primarily in North America, Europe, and Asia-Pacific.The company's revenue model is based on B2B transactions through subscription agreements for their therapeutic products. Clients typically enter into service agreements that include annual subscriptions or tiered pricing options for accessing the company's therapies. Through strategic partnerships with distributors, Elevation Oncology enhances its market presence, ensuring a steady stream of recurring revenue.In June 2021, Elevation Oncology, Inc. completed an IPO, raising USD 100 mn by selling 6.25 million shares at USD 16 each on the NASDAQ. The funding will be utilized for advancing their pipeline of innovative therapies and expanding their market presence. The company aims to introduce new products targeting additional oncogenic drivers and is strategically planning to expand into European and Asian markets by 2023.

## Funding rounds

- Series B, Nov 10, 2020, $65M — Vivo Capital, Aisling Capital, Qiming Venture Partners, Driehaus Capital Management, VenBio, BVF Partners, Cormorant Asset Management, Boxer Capital, Vertex Ventures HC, Janus Henderson Investors, Samsara BioCapital
- Series A, Jul 21, 2020, $33M — Aisling Capital, Qiming Venture Partners, Driehaus Capital Management, BVF Partners, Vertex Ventures HC

## Investors

- Aisling Capital (https://capitalatlas.ai/funds/aisling-capital) — Series A, Series B
- Qiming Venture Partners (https://capitalatlas.ai/funds/qiming-venture-partners) — Series A, Series B
- Driehaus Capital Management (https://capitalatlas.ai/funds/driehaus-capital-management) — Series A, Series B
- BVF Partners (https://capitalatlas.ai/funds/bvf-partners) — Series A, Series B
- Vertex Ventures HC (https://capitalatlas.ai/funds/vertex-ventures-hc) — Series A, Series B
- Vivo Capital (https://capitalatlas.ai/funds/vivo-capital) — Series B
- VenBio (https://capitalatlas.ai/funds/venbio) — Series B
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series B
- Boxer Capital (https://capitalatlas.ai/funds/boxer-capital) — Series B
- Janus Henderson Investors — Series B
- Samsara BioCapital (https://capitalatlas.ai/funds/samsara-biocapital) — Series B